Free shipping on all orders over $ 500

Anakinra

Cat. No. M10139
Anakinra Structure
Synonym:

Raleukin; AMG-719

Size Price Availability
10mg USD 530  USD530 Out of stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Anakinra (Raleukin) is an antagonist of recombinant, nonglycosylated human IL-1R. Anakinra is the first biological agent to block the pro-inflammatory effects. In vivo, combined Etanercept (5 mg/kg, ip) and Anakinra (100 mg/kg, ip. daily for 7 days) substantially improves marginal mass human islet engraftment in immunodeficient mice. Anakinra enhances tumor growth inhibition in mice receiving peptide vaccination and β-(1-3),(1-6)-D-glucan.

Product Citations
Chemical Information
Molecular Weight 509.56
Formula C20H23N5O7S2
CAS Number 143090-92-0
Storage 2-8°C, do not freeze
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] B Naziruddin, et al. Am J Transplant. Improved outcomes of islet autotransplant after total pancreatectomy by combined blockade of IL-1β and TNFα

[2] M McCall, et al. Am J Transplant. Anakinra potentiates the protective effects of etanercept in transplantation of marginal mass human islets in immunodeficient mice

[3] Ulf Harnack, et al. Anticancer Res. IL-1 receptor antagonist anakinra enhances tumour growth inhibition in mice receiving peptide vaccination and beta-(1-3),(1-6)-D-glucan

Related IL Receptor/Related Products
HB0017

HB0017 is a monoclonal antibody that targets interleukin-17 (IL-17) and selectively binds IL-17A, thereby preventing IL-1717A from binding to its receptor.

Rademikibart

Rademikibart is a human IgG4ҡ monoclonal antibody that targets IL-4 Rα to block inflammatory signaling induced by IL-4 and IL-13, two important cytokines that drive allergic inflammation, and binds to the human IL-4Rα epitope with a KD of 20.7 pM. Rademikibart does not bind to IL-4Rα from other species. Rademikibart does not bind to IL-4Rα of other species.Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation, and TARC production in PBMC, and can be used in studies related to moderate-to-severe Th2 inflammatory diseases.

Stapokibart

Stapokibart is a humanized monoclonal antibody targeting IL-4Rα that blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit, IL-4Rα. Stapokibart is able to interact with IL-4Rα in humans, cynomolgus monkeys, and rats, and can be used in atopic dermatitis research.

Erepdekinra

Erepdekinra is an interleukin-17A (IL-17A) receptor antagonist.

AF12198

AF12198 is a potent, selective and specific peptide antagonist for human type I interleukin-1 receptor (IL1-R1) (IC50=8 nM) but not the human type II receptor (IC50=6.7 µM) or the murine type I receptor (IC50>200 µM).

  Catalog
Abmole Inhibitor Catalog




Keywords: Anakinra, Raleukin; AMG-719 supplier, IL Receptor/Related, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.